医学信息
醫學信息
의학신식
Medical Information
2015年
39期
71-72
,共2页
心痛康片%冠心病%不稳定型心绞痛
心痛康片%冠心病%不穩定型心絞痛
심통강편%관심병%불은정형심교통
Xintongkang tablets%Coronary heart disease%Unstable angina pectoris
目的：探讨心痛康片治疗冠心病不稳定型心绞痛临床疗效和安全性。方法98例冠心病心绞痛患者随机分为心痛康组和常规组，常规组予以常规治疗，心痛康组后者同时加用心痛康片(江苏正大清江制药有限公司生产)，治疗3个月，观察两组的治疗总有效率和不良反应情况。结果心痛康组治疗总有效率达95.9%，常规组总有效率达69.3%。心痛康组明显高于常规组，差异具有统计学意义(<0.05)。未见明显药物相关不良反应发生。结论心痛康片治疗冠心病不稳定型心绞痛临床疗效确切、安全无明显不良反应。
目的：探討心痛康片治療冠心病不穩定型心絞痛臨床療效和安全性。方法98例冠心病心絞痛患者隨機分為心痛康組和常規組，常規組予以常規治療，心痛康組後者同時加用心痛康片(江囌正大清江製藥有限公司生產)，治療3箇月，觀察兩組的治療總有效率和不良反應情況。結果心痛康組治療總有效率達95.9%，常規組總有效率達69.3%。心痛康組明顯高于常規組，差異具有統計學意義(<0.05)。未見明顯藥物相關不良反應髮生。結論心痛康片治療冠心病不穩定型心絞痛臨床療效確切、安全無明顯不良反應。
목적：탐토심통강편치료관심병불은정형심교통림상료효화안전성。방법98례관심병심교통환자수궤분위심통강조화상규조，상규조여이상규치료，심통강조후자동시가용심통강편(강소정대청강제약유한공사생산)，치료3개월，관찰량조적치료총유효솔화불량반응정황。결과심통강조치료총유효솔체95.9%，상규조총유효솔체69.3%。심통강조명현고우상규조，차이구유통계학의의(<0.05)。미견명현약물상관불량반응발생。결론심통강편치료관심병불은정형심교통림상료효학절、안전무명현불량반응。
Objective To investigate the Xintongkang tablets in the treatment of unstable angina pectoris clinical curative ef ect and safety. Methods 98 cases of patients with angina pectoris were randomly divided into Xintongkang group and normal group, conventional group received routine treatment, while the lat er group Xintongkang with Xintongkang tablets (Jiangsu Zhengda Qingjiang Pharmaceutical Co. Ltd., March) treatment, observe the treatment of two groups of the total ef iciency and adverse reactions. Results Xintongkang group total ef ective rate was 95.9% in the conventional group, the total ef ective rate was 69.3%. Heartache Kang group was significantly higher than that of the conventional group, the dif erence was statistical y significant (P<0.05). No significant drug related adverse reaction occurred. Conclusion Xintongkang tablets in the treatment of unstable angina pectoris of coronary heart disease clinical curative ef ect, safety and no obvious adverse reaction.
